JP6655625B2 - ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用 - Google Patents

ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用 Download PDF

Info

Publication number
JP6655625B2
JP6655625B2 JP2017539508A JP2017539508A JP6655625B2 JP 6655625 B2 JP6655625 B2 JP 6655625B2 JP 2017539508 A JP2017539508 A JP 2017539508A JP 2017539508 A JP2017539508 A JP 2017539508A JP 6655625 B2 JP6655625 B2 JP 6655625B2
Authority
JP
Japan
Prior art keywords
body weight
treatment
dose
osteoarthritis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531042A5 (Direct
JP2017531042A (ja
Inventor
ホセプ、ホメデス−ベギュエル
ダビド、サバテ−エリアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecuphar Nv
Original Assignee
Ecuphar Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecuphar Nv filed Critical Ecuphar Nv
Publication of JP2017531042A publication Critical patent/JP2017531042A/ja
Publication of JP2017531042A5 publication Critical patent/JP2017531042A5/ja
Application granted granted Critical
Publication of JP6655625B2 publication Critical patent/JP6655625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017539508A 2014-10-16 2015-10-13 ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用 Active JP6655625B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382396.1A EP3009137A1 (en) 2014-10-16 2014-10-16 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals
EP14382396.1 2014-10-16
PCT/EP2015/073635 WO2016059028A1 (en) 2014-10-16 2015-10-13 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals

Publications (3)

Publication Number Publication Date
JP2017531042A JP2017531042A (ja) 2017-10-19
JP2017531042A5 JP2017531042A5 (Direct) 2018-08-23
JP6655625B2 true JP6655625B2 (ja) 2020-02-26

Family

ID=51844648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017539508A Active JP6655625B2 (ja) 2014-10-16 2015-10-13 ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用

Country Status (20)

Country Link
US (1) US11154536B2 (Direct)
EP (2) EP3009137A1 (Direct)
JP (1) JP6655625B2 (Direct)
CN (2) CN115154465A (Direct)
AR (1) AR102295A1 (Direct)
CA (1) CA2964428C (Direct)
CY (1) CY1123243T1 (Direct)
DK (1) DK3206684T3 (Direct)
ES (1) ES2828435T3 (Direct)
HR (1) HRP20201233T1 (Direct)
HU (1) HUE050511T2 (Direct)
LT (1) LT3206684T (Direct)
MX (1) MX376725B (Direct)
PL (1) PL3206684T3 (Direct)
PT (1) PT3206684T (Direct)
RS (1) RS60777B1 (Direct)
SI (1) SI3206684T1 (Direct)
SM (1) SMT202000415T1 (Direct)
TW (1) TWI707678B (Direct)
WO (1) WO2016059028A1 (Direct)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109303784B (zh) * 2018-09-30 2020-06-23 山东省文登整骨医院 痛风性关节炎动物模型的构建方法
CA3137682A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
EP4029502A1 (en) 2021-01-15 2022-07-20 Ecuphar N.V. Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
US12208085B2 (en) 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773615B2 (en) * 1997-05-05 2004-05-27 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
AU2006223498A1 (en) * 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity

Also Published As

Publication number Publication date
ES2828435T3 (es) 2021-05-26
DK3206684T3 (da) 2020-08-10
HRP20201233T1 (hr) 2020-11-13
EP3206684A1 (en) 2017-08-23
MX2017004899A (es) 2018-02-12
HUE050511T2 (hu) 2020-12-28
PL3206684T3 (pl) 2021-01-11
LT3206684T (lt) 2020-10-12
US11154536B2 (en) 2021-10-26
PT3206684T (pt) 2020-08-24
SMT202000415T1 (it) 2020-11-10
TW201625239A (zh) 2016-07-16
CN107257684A (zh) 2017-10-17
AR102295A1 (es) 2017-02-15
CA2964428C (en) 2022-01-04
RS60777B1 (sr) 2020-10-30
TWI707678B (zh) 2020-10-21
US20170231961A1 (en) 2017-08-17
SI3206684T1 (sl) 2020-11-30
CA2964428A1 (en) 2016-04-21
EP3206684B1 (en) 2020-06-17
WO2016059028A1 (en) 2016-04-21
CY1123243T1 (el) 2021-10-29
CN115154465A (zh) 2022-10-11
JP2017531042A (ja) 2017-10-19
EP3009137A1 (en) 2016-04-20
MX376725B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
US11786487B2 (en) Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
McCarthy et al. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis
TW201615221A (zh) 炎症用藥臨床新應用
JP6655625B2 (ja) ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用
JP2006520803A5 (Direct)
US9993496B1 (en) Method of administering hyaluronan formulation for supporting joint health
Malone Managing chronic arthritis
KR102419769B1 (ko) 약물 조성물
Clegg et al. Drugs used to treat osteoarthritis in the horse
US9687518B2 (en) Medicament for treating muscle and skeletal diseases
Koch et al. Principles of Therapy for Lameness: SYSTEMIC/PARENTERAL
Elmajee et al. Knee osteoarthritis: current insights into pathophysiology and non-surgical management options
Neumann et al. Effectiveness of the homeopathic preparation Zeel compared with carprofen in dogs with osteoarthritis
McKune Clinical Management and Pharmacologic Treatment of Pain
US20100203146A1 (en) Intermittent dosing strategy for treating rheumatoid arthritis
Smith et al. Treatment of equine joint diseases Part 1: Pharmacological management of equine osteoarthritis (OA)
Farisse et al. P. 5. c. 006 Modulation of secondary binge-eating disorders by topiramate: a post surgery and radiotherapy panhypopituitary case
Pucheu et al. Multicentric, randomized and positive-controlled study to assess the efficacy of an association of chondroitin sulphate, chitosan, l-selenomethionine and epigallocatechin-3-gallate in the control of osteoarthritis and functional postoperative recovery
Haque et al. Progressive Glioblastoma Multiforme in a Patient with Sickle Cell Beta Thalassemia, Observations Following Combining Valproic Acid with Hydroxyurea
Bolt Equine degenerative joint disease–medical treatment and management
Minko et al. Nanotechnology Approach for Inhalation Treatment of Pulmonary (Lung) Fibrosis
LASCELLES Supportive Care for
Spelts et al. Pain Management
NZ750691B2 (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200203

R150 Certificate of patent or registration of utility model

Ref document number: 6655625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250